- ChromaTan received a $1.73 Million Fast-Track Phase II SBIR grant award for the development of ICS – Integrated Continuous and Single-use bio-production platform. The development efforts over the next 3 years will focus on integrating CTC technology with perfusion bioreactors resulting in the first of its kind single-use platform for producing and purifying biologics in a continuous manner.
- ChromaTan raises additional $170,000 of convertible debt from new investors!
- ChromaTan is featured in GEN magazine company profile!
Read article here: ChromaTan Purifies against the Current
- ChromaTan files a PCT patent for new claims on CTC system improvements, additional operational modes and methods!
- ChromaTan publishes a landmark peer reviewed paper in the special addition of the Journal of Biotechnology on Continuous processing. This publication was more than 1 year in the making, and involved collaborations and co-authorships from Penn State University, Fujifilm Diosynth, and Regeneron!
Read publication here: Purification of monoclonal antibodies from clarified cell culture fluid using Protein A capture continuous countercurrent tangential chromatographyMarch 2015
- ChromaTan is featured in GEN magazine’s Bioprocessing Perspective! Click here to read article.
- ChromaTan submits a major publication to Journal of Biotechnology. The paper is co-written with Penn State, Fujifilm Diosynth and Regeneron Pharmaceuticals.
- ChromaTan completes the CTC demo system and starts the ChromaTan blitz - a technology demonstration campaign with our first early adoption candidate.
- ChromaTan receives additional funding from NIH on the Phase II extension for $175,000!
June - October 2014
- ChromaTan presented data that was jointly generated with Fujifilm Diosynth and Regeneron Pharmaceuticals at several industry conferences including Prep, Recovery, ManuBio and Bioprocess International. The results showed 4-5 times productivity increase over the status quo technology with comparable purity and yield. The data causes significant excitement in the industry and leads to several technology evaluation requests from major antibody manufacturers.
- ChromaTan was awarded Phase II funding from the National Institute of Helath (NIH) for $985,000! This is a major milestone for our team and serves as a major validation for all the hard work that our team has been doing!
Some excerpts from the summary review statements:
"... This Phase II project has high significance because it describes a way to more cheaply purify proteins on large scale as needed for biopharmaceutical production. The innovation is high because the basic concept of the chromatography is new and appears to offer significant advantages"
".... This is an exciting prospect for those that depend on the production of such compounds. This is highly significant"
"... The CCTC system is a novel approach to using selective resins, like Protein A, in the purification of large amounts of protein. The resin is efficiently used unlike a conventional column where much of the column is “waiting” for the sample. This is clever engineering."
- ChromaTan was recently awarded an investment of $225,000 from Ben Franklin Technology Partners of Central PA! The funds will be used to boost the development of CCTC and increase ChromaTan's headcount to five!
- ChromaTan and ASI have been featured on Pharmaceutical Technology in the article entitled "Single-Use Continuous Chromatography Overcoming Limitations of Traditional Protein Purification" by Dr. Cynthia Challener. Below is a short blurb:
Continuous countercurrent tangential chromatography combines the principles of chromatography and continuous/conveyor-belt processing with liquid–liquid extraction and tangential flow filtration to create the first “true moving bed” technology (as opposed to simulated moving bed) that is capable of large-scale, column-free capture purification of biologics, according to Shinkazh.Initially developed by Chromatan and now under joint development by Chromatan and ASI, the Evopure system preserves the robust resin interaction and buffer chemistry of column chromatography while using a flow path specifically designed for single-use operation.The Evopure system addresses three critical needs of the purification industry—cost savings on capital and operational costs, a single-use and sterile flow path, and linear scalability, according to Smeltz. Specifically, with CCTC, throughput is increased 5- to 10-fold when compared to conventional columns, which enables high resin cycling in a single batch. CCTC thus, makes single-use capture practical and introduces significant cost savings of up to 65% to the end user, according to Shinkazh.
- ChromaTan publishes "Continuous Countercurrent Tangential Chromatography for Monoclonal Antibody Purification", a landmark paper in Separation Science and Technology!
- ChromaTan and ASI has signed a strategic partnership deal.
ChromaTan a single-use chromatography solutions provider and ASI, manufacturer of single-use systems and technologies, announced today an exclusive agreement between the two companies to combine development, sales, marketing and manufacturing efforts to bring CCTC-a continuous, single-use and column-free purification technology to market. This agreement leveragesthe strengths of ASI’s single-use manufacturing, sales and marketing expertise with ChromaTan’s innovative scientific and technical development expertise.
- In-Pharma technologist highlights ChromaTan's partnership with ASI with exclusive podcast interview of ASI's president Kent Smeltz and ChromaTan's CEO Oleg Shinkazh! Click here to listen to the podcast (Internet Explorer is recommended).
- ChromaTan closes the seed round at $560,815 by raising $227,815 from angel investors, friends and family!
- ChromaTan featured in Centre Daily Times news article "Programs, Grants Help Boost Business"!
- ChromaTan welcomes our new VP of engineering Boris Napadensky!
- ChromaTan moves into new office and laboratory space in the wonderful technology incubator at 200 Innovation park in State College, PA
- ChromaTan is funded by Ben Franklin Technology Partners of Central PA with a $150,000 debt investment!
- ChromaTan signs a material transfer agreement with FujiFilm Diosynth
- ChromaTan hires Dr. Achyuta Teella to begin work on the continuous CTC prototype system! Welcome aboard!
- ChromaTan received an Phase 1 SBIR Award from the National Institute of Health (NIH) for $183,000 to construct a pilot Countercurrent Tangential Chromatography system!
- ChromaTan's Countercurrent Tangential Chromatography Methods, Systems, And Apparatus patent has been issued! You may download a PDF copy of the patent from the Intellectual Property section for review.
- ChromaTan's Continuous Countercurrent Tangential Chromatography System patent has been issued! You may download a PDF copy of the patent from the Intellectual Property section for review.
- ChromaTan's article titled 'Countercurrent tangential chromatography for large-scale protein purification' has been published in Volume 108, Issue 3 March 2011 of Biotechnology and Bioengineering.
- ChromaTan advances to the finals of Masschallenge! Masschallenge is a competition for startup companies. ChromaTan will be moving into the accelerator stage of the program for a chance to win $100,000 dollars! More details at http://www.masschallenge.com.
- ChromaTan wins funding grant from Ben Franklin Technology Partners.
- Spectrum is now an investor in ChromaTan.
- Getting Real with Downstream Processing, GEN
"Like all areas of bioprocessing, downstream purification has its own favored buzzwords—titers, bottlenecks, capacity, and others—meant to evoke a particular response depending on who is speaking or writing them. But, if we could just identify one leading, universal trend in downstream bioprocessing, it would be simplification."
- The ChromaTan team successfully created an innovative solution in countercurrent chromatography at the Penn State University Fenske Laboratory based on a patent pending design.
- Feasibility studies completed - BSA/Myoglobin separation, excellent recovery, purity and hydrodynamic stability achieved.
- Partnership with Penn State and Dr. Andrew Zydney established.
- Patent filed.
- ChromaTan is officially incorporated.